Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...
2don MSN
Is Eli Lilly a Buy Before 2026?
Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...
Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...
We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...
Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to ...
Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...
INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3, with total ...
(Reuters) - U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former CFO Anat Ashkenazi stepped ...
Eli Lilly and Co. on Monday elevated a company insider to chief financial officer, succeeding Anat Ashkenazi, who left three months ago to join Google and Alphabet. Lucas Montarce, who has been with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback